The long term objective of our combined chemical, pharmacokinetic, and radiobiological studies is to develop a rational method for selecting radioprotective drugs which will be useful in clinical radiotherapy with low dose/fraction of photons or cyclotron neutrons. Mechanistic and pragmatic studies will be performed with WR2721 and phosphorothioate congeners to relate drug structure and metabolism to desirable biological properties, acceptable toxicity and ability to protect selected normal tissues more than tumors against radiation. Selected protectors will be evaluated in biodistribution and metabolism studies in vivo and in vitro. Partition coefficients, ability to cross cell membranes in an RBC model system, removal of the -PO3 group protecting the active SH group and breakdown to various metabolites will be measured. HPLC, GPC, LSC and diffusible substance autoradiography techniques will be applied to 35S labeled protectors synthesized in our research group. NMR will be used to measure metabolites of 33S labeled drugs. Protector metabolism in vivo will be compared with measures of endogenous thiols. Mouse ascites tumors (a model """"""""in vivo cell suspension"""""""") will be used as a screen. In vitro colony forming ability of tumor cells irradiated +/- protector will allow quantitation of radioprotection at multiple dose levels and may allow an estimate of modification of the single hit component of radiation injury, important for cell kill at low doses. Based on these combined data, we will select protectors in addition to WR 2721 for further testing in pragmatic studies with photons and cyclotron neutrons. Radioprotection will be measured in rats using functional and/or quantitative endpoints in three tissues which may be dose limiting in radiotherapy. These are: kidney (glomerular filtration rate, effective renal plasma flow, quantitative histology); salivary gland (saliva flow, electrolyte levels, production of enzymes of ductal and acinar origin); and brain (quantitative histopathology). Protection also will be measured in transplanted mouse tumors (RIF-1, EMT-6, KHT) irradiated in vivo and assayed by colony forming ability in vitro, to indicate potential for therapeutic gain.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036485-04
Application #
3174078
Study Section
(SSS)
Project Start
1983-12-01
Project End
1988-03-31
Budget Start
1986-12-01
Budget End
1988-03-31
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Shankland, E G; Livesey, J C; Wiseman, R W et al. (2002) Multinuclear NMR studies of an actively dividing artificial tumor. Physiol Res 51:49-58
Spence, A M; Rasey, J S; Dwyer-Hansen, L et al. (1995) Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates. Radiother Oncol 35:216-26
Sriram, R; Ali-Osman, F (1993) Purification and biochemical characterization of gamma-glutamylcysteine synthetase from a human malignant astrocytoma cell line. Biochem Mol Biol Int 30:1053-60
Livesey, J C; Golden, R N; Shankland, E G et al. (1992) Magnetic resonance spectroscopic measurement of cellular thiol reduction-oxidation state. Int J Radiat Oncol Biol Phys 22:755-7
Badger, C C; Rasey, J; Nourigat, C et al. (1991) WR2721 protection of bone marrow in 131I-labeled antibody therapy. Radiat Res 128:320-4
Rasey, J S; Magee, S; Nelson, N et al. (1990) Response of mouse tissues to neutron and gamma radiation: protection by WR-3689 and WR-77913. Radiother Oncol 17:167-73
Grunbaum, Z; Kroll, K; Greene, J L et al. (1990) Synthesis and radiobiological applications of [35S]L-homocysteine thiolactone. Int J Rad Appl Instrum B 17:473-8
Srivenugopal, K S; Ali-Osman, F (1990) Stimulation and inhibition of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col E1 plasmid deoxyribonucleic acid by polyamines and inorganic cations. Biochem Pharmacol 40:473-9
Livesey, J C; Grunbaum, Z; Krohn, K A (1990) Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins. Biochem Pharmacol 39:1807-12
Livesey, J C; Golden, R N; Shankland, E G et al. (1989) Measurement of tissue oxidation-reduction state with carbon-13 nuclear magnetic resonance spectroscopy. Cancer Res 49:1937-40

Showing the most recent 10 out of 21 publications